Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05867017 · ClinicalTrials.gov registry record
Long-Term Sequelae of SARS-COV-2 Infection: Diabetes Mellitus
A clinical trial, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- 23
- Enrollment target
NCT05867017: Completed study, sponsored by The University of Texas Health Science Center at San Antonio.
NCT05867017 is a clinical trial that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 23 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05867017 has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- 23 participants
- Enrollment target
Study Summary
Hospitalized patients with severe COVID-19 have an increased incidence of insulin resistance, impaired beta cell function, glucose intolerance (prediabetes), and overt type 2 diabetes (T2D) compared to non-hospitalized patients with COVID-19 and COVID-19 negative individuals on long-term follow up.
Primary Outcome
Change in HbA1c, and indication of glucose levels over a 3 month period
Interventions
- OTHER Measure of physiologic parameters
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2023-07-10 |
| Est. Completion | 2025-11-30 |
What the finished NCT05867017 record still lists
NCT05867017 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 23 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Measure of physiologic parameters is the first listed.
NCT05867017 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05867017 about?
NCT05867017 is a clinical study titled "Long-Term Sequelae of SARS-COV-2 Infection: Diabetes Mellitus". Hospitalized patients with severe COVID-19 have an increased incidence of insulin resistance, impaired beta cell function, glucose intolerance (prediabetes), and overt type 2 diabetes (T2D) compared to non-hospitalized patients with COVID-19 and COVID-19 negative individuals on long-term follow up.
What is the current status of trial NCT05867017?
This trial is currently completed. The enrollment target is 23 participants. The study started on 2023-07-10. Estimated completion is 2025-11-30.
What interventions are being tested in trial NCT05867017?
The interventions under investigation include: Measure of physiologic parameters (OTHER).
Who is sponsoring clinical trial NCT05867017?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI